dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Calcitonin receptors (type: gpcr)
Target: AM<sub>1</sub> receptor

Ligand: adrenomedullin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Receptor activity modifying proteins interaction with human and porcine calcitonin receptor-like receptor (CRLR) in HEK-293 cells.
Published in: Mol Cell Biochem

Ligand: adrenomedullin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8 pIC50
Reference (Journal): Three receptor-activity-modifying proteins define calcitonin gene-related peptide or adrenomedullin selectivity of the mouse calcitonin-like receptor in COS-7 cells.
Published in: Biochem Pharmacol

Ligand: adrenomedullin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor.
Published in: Nature

Ligand: adrenomedullin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Mammalian calcitonin receptor-like receptor/receptor activity modifying protein complexes define calcitonin gene-related peptide and adrenomedullin receptors in Drosophila Schneider 2 cells.
Published in: FEBS Lett

Ligand: adrenomedullin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat.
Published in: Eur J Neurosci

Ligand: adrenomedullin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Mouse receptor-activity-modifying proteins 1, -2 and -3: amino acid sequence, expression and function.
Published in: Mol Cell Endocrinol

Ligand: adrenomedullin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1.
Published in: Endocrinology

Ligand: adrenomedullin 2/intermedin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25.
Published in: Br J Pharmacol

Ligand: α-CGRP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6 pKd
Reference (Journal): RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor.
Published in: Nature

Ligand: α-CGRP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.6 pIC50
Reference (Journal): Mammalian calcitonin receptor-like receptor/receptor activity modifying protein complexes define calcitonin gene-related peptide and adrenomedullin receptors in Drosophila Schneider 2 cells.
Published in: FEBS Lett
Target family: Calcitonin receptors (type: gpcr)
Target: AMY<sub>1</sub> receptor

Ligand: amylin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.
Published in: Endocrinology
Target family: Calcium activated chloride channel (CaCC) (type: other_ic)
Target: CaCC

Ligand: niflumic acid (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: MONNA (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.099999904632568 pIC50
Reference (Journal): Substituted 2-Acylaminocycloalkylthiophene-3-carboxylic Acid Arylamides as Inhibitors of the Calcium-Activated Chloride Channel Transmembrane Protein 16A (TMEM16A).
Published in: J Med Chem

Ligand: mibefradil (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1997)
Median affinity:  -

Ligand: Ins(3,4,5,6)P4 (Metabolite)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: fluoxetine (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1987)
Median affinity:  -

Ligand: flufenamic acid (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Median affinity:  -

Ligand: DIDS (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: DCDPC (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: crofelemer (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2012)
Primary target: yes
Median affinity: 5.190000057220459 pIC50
Reference (Journal): Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels.
Published in: Mol Pharmacol

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -

Ligand: CaCCinh-A01 (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Small-molecule screen identifies inhibitors of a human intestinal calcium-activated chloride channel.
Published in: Mol Pharmacol

Ligand: Ani9 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.96999979019165 pIC50
Reference (Journal): Ani9, A Novel Potent Small-Molecule ANO1 Inhibitor with Negligible Effect on ANO2.
Published in: PLoS One

Ligand: 9-anthroic acid (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: NPPB (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: SITS (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -

Ligand: tannic acid (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  -
Target family: Calcium- and sodium-activated potassium channels (K<sub>Ca</sub>, K<sub>Na</sub>) (type: vgic)
Target: K<sub>Ca</sub>2.2

Ligand: chlorzoxazone (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (1958)
Primary target: no
Median affinity:  pEC50
Reference (Journal): Pharmacological activation of cloned intermediate- and small-conductance Ca(2+)-activated K(+) channels.
Published in: Am J Physiol, Cell Physiol

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Small-conductance, calcium-activated potassium channels from mammalian brain.
Published in: Science

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Gating of recombinant small-conductance Ca-activated K+ channels by calcium.
Published in: J Gen Physiol

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Ca2+-activated K+ channels in human leukemic Jurkat T cells. Molecular cloning, biochemical and functional characterization.
Published in: J Biol Chem

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Mechanism of calcium gating in small-conductance calcium-activated potassium channels.
Published in: Nature

Ligand: Ca2+ (Inorganic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Specific enhancement of SK channel activity selectively potentiates the afterhyperpolarizing current I(AHP) and modulates the firing properties of hippocampal pyramidal neurons.
Published in: J Biol Chem

Ligand: bicuculline (Natural product)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 4.599999904632568 pIC50
Reference (Journal): Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells.
Published in: Br J Pharmacol

Ligand: apamin (Peptide)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity: 9.399999618530273 pKd
Reference (Journal): SK2 encodes the apamin-sensitive Ca(2+)-activated K(+) channels in the human leukemic T cell line, Jurkat.
Published in: FEBS Lett

Ligand: apamin (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Small-conductance, calcium-activated potassium channels from mammalian brain.
Published in: Science

Ligand: apamin (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells.
Published in: Br J Pharmacol
Target family: Calcium- and sodium-activated potassium channels (K<sub>Ca</sub>, K<sub>Na</sub>) (type: vgic)
Target: K<sub>Ca</sub>1.1

Ligand: toxin BmP09 (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 7.6 pEC50
Reference (Journal): BmP09, a &quot;long chain&quot; scorpion peptide blocker of BK channels.
Published in: J Biol Chem

Ligand: tetraethylammonium (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: slotoxin (Peptide)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity: 8.8 pKd
Reference (Journal): Slotoxin, alphaKTx1.11, a new scorpion peptide blocker of MaxiK channels that differentiates between alpha and alpha+beta (beta1 or beta4) complexes.
Published in: FEBS Lett

Ligand: rimtuzalcap (Synthetic organic)
Interaction type: Allosteric modulator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Patent): Potassium channel modulators

Ligand: paxilline (Synthetic organic)
Interaction type: Inhibitor
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.720000267028809 pKi
Reference (Journal): Paxilline inhibition of the alpha-subunit of the high-conductance calcium-activated potassium channel.
Published in: Neuropharmacology

Ligand: NS1643 (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Modulation of the Ca(2+)-dependent K+ channel, hslo, by the substituted diphenylurea NS 1608, paxilline and internal Ca2+.
Published in: Neuropharmacology

Ligand: NS1619 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: NS11021 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pEC50
Reference (Journal): The small molecule NS11021 is a potent and specific activator of Ca2+-activated big-conductance K+ channels.
Published in: Mol Pharmacol

Ligand: NS004 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: iberiotoxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: flindokalner (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity: 6.5 pEC50
Reference (Journal): Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels.
Published in: Nat Med

Ligand: charybdotoxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: 17β-estradiol (Metabolite)
Interaction type: Activator
Action: None
Ligand approved: yes
Approval source: FDA (1954, prior history unavailable)
Median affinity: 5.6 pEC50
Reference (Journal): Acute activation of Maxi-K channels (hSlo) by estradiol binding to the beta subunit.
Published in: Science
Target family: Calcium- and sodium-activated potassium channels (K<sub>Ca</sub>, K<sub>Na</sub>) (type: vgic)
Target: K<sub>Ca</sub>5.1

Ligand: quinidine (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity:  -
Reference (Journal): Mechanism of inhibition of mouse Slo3 (KCa 5.1) potassium channels by quinine, quinidine and barium.
Published in: Br J Pharmacol

Ligand: quinidine (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity:  -
Reference (Journal): Pharmacology of hSlo3 channels and their contribution in the capacitation-associated hyperpolarization of human sperm.
Published in: Biochem Biophys Res Commun

Ligand: quinidine (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity:  -
Reference (Journal): Block of mouse Slo1 and Slo3 K+ channels by CTX, IbTX, TEA, 4-AP and quinidine.
Published in: Channels (Austin)

Ligand: NS1619 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: NS004 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: CAMK1 family (type: enzyme)
Target: calcium/calmodulin dependent protein kinase ID

Ligand: bosutinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2012), EMA (2013)
Primary target: no
Median affinity: 7.039999961853027 pIC50
Reference (Journal): Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Published in: Leukemia
Target family: CAMK2 family (type: enzyme)
Target: calcium/calmodulin-dependent protein kinase II alpha subunit

Ligand: KN-93 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 5.079999923706055 pIC50
Reference (Journal): Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic antineuroinflammatory compound.
Published in: J Med Chem

Ligand: KN-93 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  pIC50
Reference (Journal): The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells.
Published in: Biochem Biophys Res Commun

Ligand: KN-93 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  pIC50
Reference (Journal): Structure and activity relationship of 2-(substituted benzoyl)-hydroxyindoles as novel CaMKII inhibitors.
Published in: Bioorg Med Chem Lett
Target family: CAMK2 family (type: enzyme)
Target: calcium/calmodulin-dependent protein kinase II beta subunit

Ligand: staurosporine (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 10 pIC50
Reference (Journal): Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
Published in: J Med Chem
Target family: CAMK2 family (type: enzyme)
Target: calcium/calmodulin-dependent protein kinase II delta subunit

Ligand: compound 15b [PMID: 18334293] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.050000190734863 pIC50
Reference (Journal): Pyrimidine-based inhibitors of CaMKIIdelta.
Published in: Bioorg Med Chem Lett

Ligand: compound 27 [PMID: 18337095] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8 pIC50
Reference (Journal): Aryl-indolyl maleimides as inhibitors of CaMKIIdelta. Part 3: Importance of the indole orientation.
Published in: Bioorg Med Chem Lett

Ligand: MELK-TI (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.090000152587891 pIC50
Reference (Journal): Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase.
Published in: ACS Med Chem Lett
Target family: CAMK2 family (type: enzyme)
Target: calcium/calmodulin-dependent protein kinase II gamma subunit

Ligand: bosutinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2012), EMA (2013)
Primary target: no
Median affinity: 6.739999771118164 pIC50
Reference (Journal): Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Published in: Leukemia
Target family: CAMK2 family (type: enzyme)
Target: Calmodulin-dependent kinase II

Ligand: calmodulin (Peptide)
Interaction type: Activator
Action: Activation
Ligand approved: no
Median affinity:  -

Ligand: compound 20 [PMID: 22136433] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.079999923706055 pIC50
Reference (Journal): 7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.
Published in: J Med Chem

Ligand: K-252a (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -
Reference (Journal): Potent and preferential inhibition of Ca2+/calmodulin-dependent protein kinase II by K252a and its derivative, KT5926.
Published in: Biochem Biophys Res Commun

Ligand: KN62 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.050000190734863 pIC50
Reference (Journal): KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II.
Published in: J Biol Chem
Target family: CAMK-unique family (type: enzyme)
Target: serine/threonine kinase 33

Ligand: compound 1 [PMID: 21742770] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.149999618530273 pIC50
Reference (Journal): STK33 kinase activity is nonessential in KRAS-dependent cancer cells.
Published in: Cancer Res
Target family: Carbonic anhydrases (type: enzyme)
Target: carbonic anhydrase 13

Ligand: acetazolamide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1995)
Primary target: no
Median affinity: 7.769999980926514 pKi
Reference (Journal): Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a less utilized binding pocket than most hydrophobic inhibitors.
Published in: Bioorg Med Chem Lett
Target family: Carbonic anhydrases (type: enzyme)
Target: carbonic anhydrase 2

Ligand: compound 5a [PMID: 31287314] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.019999980926514 pKi
Reference (Journal): Synthesis and Evaluation of Carbonic Anhydrase Inhibitors with Carbon Monoxide Releasing Properties for the Management of Rheumatoid Arthritis.
Published in: J Med Chem

Ligand: compound 5b [PMID: 31287314] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.670000076293945 pKi
Reference (Journal): Synthesis and Evaluation of Carbonic Anhydrase Inhibitors with Carbon Monoxide Releasing Properties for the Management of Rheumatoid Arthritis.
Published in: J Med Chem

Ligand: salvianolic acid A (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.019999980926514 pKi
Reference (Journal): New natural product carbonic anhydrase inhibitors incorporating phenol moieties.
Published in: Bioorg Med Chem
Target family: Carbonic anhydrases (type: enzyme)
Target: carbonic anhydrase 5A

Ligand: amphetamine (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (no history prior to 1976)
Primary target: no
Median affinity:  -
Reference (Journal): Sulfur, selenium and tellurium containing amines act as effective carbonic anhydrase activators.
Published in: Bioorg Chem

Ligand: histamine (Metabolite)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Sulfur, selenium and tellurium containing amines act as effective carbonic anhydrase activators.
Published in: Bioorg Chem

Ligand: L-histidine (Metabolite)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII, and XIV with l- and d-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme.
Published in: Chemistry
Target family: Carbonic anhydrases (type: enzyme)
Target: carbonic anhydrase 9

Ligand: compound 5a [PMID: 31287314] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.380000114440918 pKi
Reference (Journal): Synthesis and Evaluation of Carbonic Anhydrase Inhibitors with Carbon Monoxide Releasing Properties for the Management of Rheumatoid Arthritis.
Published in: J Med Chem

Ligand: compound 5b [PMID: 31287314] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5 pKi
Reference (Journal): Synthesis and Evaluation of Carbonic Anhydrase Inhibitors with Carbon Monoxide Releasing Properties for the Management of Rheumatoid Arthritis.
Published in: J Med Chem

Ligand: SLC-0111 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.349999904632568 pKi
Reference (Journal): Synthesis of sulfonamides incorporating piperazinyl-ureido moieties and their carbonic anhydrase I, II, IX and XII inhibitory activity.
Published in: Bioorg Med Chem Lett